Protein expression profiling reveals distinctive changes in serum proteins associated with chronic pancreatitis

Pancreas

Volumn 35, Issue 4, 2007, Pages 334-342

  Hartmann, Daniel ^a   Felix, Klaus ^a   Ehmann, Michael ^a   Schnölzer, Martina ^b   Fiedler, Sabine ^b   Bogumil, Ralf ^c   Büchler, Markus ^a   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c BioTechnologieZentrum Hennigsdorf   (Germany)

Author keywords

Biomarker; Chronic pancreatitis; SELDI TOF MS; Serum proteomics

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; COPPER; PREALBUMIN; PROTEIN; RETINOL BINDING PROTEIN;

ADULT; ANION EXCHANGE; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PURIFICATION; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AMYLOID; ANION EXCHANGE RESINS; APOLIPOPROTEIN A-II; APOLIPOPROTEIN C-I; APOLIPOPROTEIN C-II; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ION EXCHANGE; MALE; MIDDLE AGED; PANCREATITIS, CHRONIC; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; REPRODUCIBILITY OF RESULTS; RETINOL-BINDING PROTEINS, PLASMA; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 37349080169     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3180cac723     Document Type: Article

References (37)

1. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433-1437.
2. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648.
3. Ebert M, Schandl L, Schmid RM. Differentiation of chronic pancreatitis from pancreatic cancer: recent advances in molecular diagnosis. Dig Dis. 2001;19:32-36.
4. Orlando RC. Mechanisms of epithelial injury and inflammation in gastrointestinal diseases. Rev Gastroenterol Disord. 2002;2(suppl 2):S2-S8.
5. Kloppel G, Detlefsen S, Feyerabend B. Fibrosis of the pancreas: the initial tissue damage and the resulting pattern. Virchows Arch. 2004;445:1-8.
6. Stevens T, Conwell DL, Zuccaro G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol. 2004;99:2256-2270.
7. Jacobson DG, Curington C, Connery K, et al. Trypsin-like immunoreactivity as a test for pancreatic insufficiency. N Engl J Med. 1984;310:1307-1309.
8. Pezzilli R, Talamini G, Gullo L. Behaviour of serum pancreatic enzymes in chronic pancreatitis. Dig Liver Dis. 2000;32:233-237.
9. Issaq HJ, Veenstra TD, Conrads TP, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun. 2002;292:587-592.
10. Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol. 2004;5:45-67.
11. Engwegen JY, Gast MC, Schellens JH, et al. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci. 2006;27:251-259.
12. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004;10:860-868.
13. Chertov O, Biragyn A, Kwak LW, et al. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. Proteomics. 2004;4:1195-1203.
14. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205-214.
15. Dominguez-Munoz JE, Pieramico O, Buchler M, et al. Clinical utility of the serum pancreolauryl test in diagnosis and staging of chronic pancreatitis. Am J Gastroenterol. 1993;88:1237-1241.
16. Malfertheiner P, Buchler M, Muller A, et al. Fluorescein dilaurate serum test: a rapid tubeless pancreatic function test. Pancreas. 1987;2:53-60.
17. Dominguez-Munoz JE, Malfertheiner P. Optimized serum pancreolauryl test for differentiating patients with and without chronic pancreatitis. Clin Chem. 1998;44:869-875.
18. Malfertheiner P, Buchler M, Muller A, et al. Influence of extrapancreatic digestive disorders on the indirect pancreatic function test with fluorescein dilaurate. Clin Physiol Biochem. 1985;3:166-173.
19. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271-284.
20. Coombes KR, Morris JS, Hu J, et al. Serum proteomics profiling - a young technology begins to mature. Nat Biotechnol. 2005;23:291-292.
21. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 2006;66:5540-5541.
22. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer. 2005;5:142-149.
23. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer. 2005;115:783-789.
24. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.
25. Beil FU, Fojo SS, Brewer HB Jr, et al. Apolipoprotein C-II deficiency syndrome due to apo C-IIHamburg: clinical and biochemical features and HphI restriction enzyme polymorphism. Eur J Clin Invest. 1992;22:88-95.
26. Taylor B. Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J Surg. 2003;27:1249-1257.
27. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882-5890.
28. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5:4589-4596.
29. Lasztity N, Biro L, Nemeth E, et al. Protein status in pancreatitis-transthyretin is a sensitive biomarker of malnutrition in acute and chronic pancreatitis. Clin Chem Lab Med. 2002;40:1320-1324.
30. McCarroll JA, Phillips PA, Santucci N, et al. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut. 2006;55:79-89.
31. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64-69.
32. Yokoi K, Shih LC, Kobayashi R, et al. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol. 2005;27:1361-1369.
33. Rau B, Steinbach G, Baumgart K, et al. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit Care Med. 2000;28:736-742.
34. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980-988.
35. Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther. 2005;4:740-746.
36. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487-491.
37. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442-446.